January 22, 2024 – In September 2020, Mr. Colombo joined Viridian as Director of Data Analytics to take over the firm’s Viridian Cannabis Deal Tracker – a data/market intelligence research platform. Launched in January 2015, the Deal Tracker was the industry’s first capital markets data service that tracks and analyzes equity, debt, M&A, and going public transactions in the Cannabis, Hemp, and Psychedelics industries. We’ve tracked and analyzed more than 6,000 transactions totaling more than $70 billion in transaction value. We know where equity investors invest, where lenders lend and where acquirers acquire. The Deal Tracker is received and read every day by thousands of leading industry players on a global basis.

Scott Greiper, President and founder of Viridian Capital, stated, “Frank Colombo brings a unique skillset to our firm and to his analysis of the cannabis and related industries. He has 20 years of experience in credit research, valuation, financial forecasting and analysis at leading investment banks, plus a deep understanding of the business of cannabis, financial modeling, and company valuations. In combination this brings great value to our advisory and investment banking clients, for capital raise and M&A transactions. His being named as Managing Director at Viridian is a testament to the enormous benefit he brings to our firm, our clients and to the industry as a whole.”

About Viridian Capital Advisors, LLC
Launched in 2014, Viridian Capital Advisors was one of the first and now leading, corporate finance, advisory and M&A practices in the legal Cannabis/CBD industries, and now in the Psychedelics sector. We represent companies, investors, lenders, buyers and sellers. Our advisory practice is meant to help “institutionalize” our clients before they go to market for capital or M&A – by helping to build a professional Board of Directors, sophisticated financial models and valuation analyses, exit strategies and strategic advisory services. Our investment banking practice raises capital and executes M&A transactions through our New York City based broker-dealer, Bradley Woods & Co. Ltd.

Viridian is widely recognized as the industry leader in research and capital markets data/market intelligence through the Viridian Deal Tracker. Launched in January 2015, and having analyzed more than $60 billion in deals, the Viridian Deal Tracker is a proprietary data service that monitors and analyzes investment, M&A activity and capital markets trends in the Cannabis/CBD and Psychedelics industries. The Deal Tracker has become a trusted and valuable source for companies, investors, lenders and sellers/acquirers to make informed capital allocation decisions.

Marijuana remains illegal under federal law. The federal government does not recognize marijuana to have any medicinal value. Marijuana cultivation, possession, consumption, sales, and distribution are illegal under federal laws and also certain state laws. Investors in cannabis may be subject to law enforcement actions. Please note that there are differences in marijuana laws from one state to another. Furthermore there are substantial risks associated with investing in cannabis companies, including, without limitation, changes in laws, rules, and regulations, risks associated with the economy, capital markets, and a company’s ability to execute on its business plan.